Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Price Target at $66.00

Maze Therapeutics, Inc. (NASDAQ:MAZE) has received an average rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $66.00.

Several brokerages recently weighed in on MAZE. JPMorgan Chase & Co. upped their price target on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. HC Wainwright upped their price target on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $29.00 on Tuesday. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -11.46 and a beta of 2.27. The business’s fifty day moving average is $25.72 and its 200 day moving average is $35.86. Maze Therapeutics has a twelve month low of $10.98 and a twelve month high of $53.65. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Research analysts expect that Maze Therapeutics will post -2.73 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jason V. Coloma sold 23,865 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $26.05, for a total value of $621,683.25. Following the sale, the chief executive officer directly owned 319,079 shares of the company’s stock, valued at approximately $8,312,007.95. This represents a 6.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the completion of the sale, the senior vice president directly owned 12,965 shares in the company, valued at approximately $381,689.60. This represents a 16.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 102,360 shares of company stock valued at $2,722,140. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors have recently modified their holdings of MAZE. Washington University lifted its holdings in shares of Maze Therapeutics by 33.3% during the fourth quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after purchasing an additional 70,121 shares in the last quarter. Mass General Brigham Inc purchased a new position in Maze Therapeutics in the 4th quarter worth about $9,943,000. ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics in the 3rd quarter worth about $14,135,000. Boothbay Fund Management LLC lifted its stake in Maze Therapeutics by 365.9% during the 3rd quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock valued at $9,124,000 after acquiring an additional 276,345 shares during the period. Finally, Eventide Asset Management LLC bought a new position in Maze Therapeutics during the 4th quarter valued at about $13,425,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.